This work is licensed under a Creative Commons Attribution 4.0 International License.
CLP
General Information
DRACP ID DRACP00875
Peptide Name CLP
Sequence LP
Sequence Length 2
UniProt ID Not available
PubChem CID Not available
Origin marine natural metabolite
Type Native peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| MDA-MB-231 | Breast adenocarcinoma | Carcinoma | IC50=73.4 μM | MTT assay | 48h | 1 |
| MDA-MB-468 | Breast adenocarcinoma | Carcinoma | IC50=67.4 μM | MTT assay | 48h | 1 |
Hemolytic Activity Human red blood cells (RBC): LC50>401 μM
Normal (non-cancerous) Cytotoxicity MCF-12A: IC50>100 μM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Not available
N-terminal Modification Lactam
C-terminal Modification Lactam
Other Modification Lactam
Chiral L
Physicochemical Information
Formula C11H20N2O3
Absent amino acids ACDEFGHIKMNQRSTVWY
Common amino acids LP
Mass 24631
Pl 6.11
Basic residues 0
Acidic residues 0
Hydrophobic residues 1
Net charge 0
Boman Index 492
Hydrophobicity 110
Aliphatic Index 195
Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 31669320
Title Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.